JP2014505096A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014505096A5 JP2014505096A5 JP2013553014A JP2013553014A JP2014505096A5 JP 2014505096 A5 JP2014505096 A5 JP 2014505096A5 JP 2013553014 A JP2013553014 A JP 2013553014A JP 2013553014 A JP2013553014 A JP 2013553014A JP 2014505096 A5 JP2014505096 A5 JP 2014505096A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- administered
- hour
- food intake
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 93
- 239000003814 drug Substances 0.000 claims 23
- 150000003943 catecholamines Chemical class 0.000 claims 21
- 229940079593 drug Drugs 0.000 claims 19
- 230000037406 food intake Effects 0.000 claims 18
- 235000012631 food intake Nutrition 0.000 claims 18
- 150000002148 esters Chemical class 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 12
- 229910019142 PO4 Inorganic materials 0.000 claims 9
- 235000021317 phosphate Nutrition 0.000 claims 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 8
- 208000018737 Parkinson disease Diseases 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 8
- 208000015114 central nervous system disease Diseases 0.000 claims 8
- 208000027232 peripheral nervous system disease Diseases 0.000 claims 8
- 238000011282 treatment Methods 0.000 claims 8
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 7
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 7
- 230000002265 prevention Effects 0.000 claims 7
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 6
- 208000016285 Movement disease Diseases 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 125000001589 carboacyl group Chemical group 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 229960004502 levodopa Drugs 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 239000010452 phosphate Substances 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 4
- 125000003282 alkyl amino group Chemical group 0.000 claims 4
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 4
- 125000003435 aroyl group Chemical group 0.000 claims 4
- 125000004429 atom Chemical group 0.000 claims 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 4
- 150000004657 carbamic acid derivatives Chemical class 0.000 claims 4
- 125000004663 dialkyl amino group Chemical group 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 239000001301 oxygen Substances 0.000 claims 4
- 239000011593 sulfur Substances 0.000 claims 4
- 125000004001 thioalkyl group Chemical group 0.000 claims 4
- 208000012902 Nervous system disease Diseases 0.000 claims 3
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims 3
- 150000003014 phosphoric acid esters Chemical class 0.000 claims 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 206010030113 Oedema Diseases 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 125000001931 aliphatic group Chemical group 0.000 claims 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 claims 2
- 229960000911 benserazide Drugs 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 239000000460 chlorine Chemical group 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- 239000011630 iodine Chemical group 0.000 claims 2
- 229910052740 iodine Chemical group 0.000 claims 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- ASOADIZOVZTJSR-UHFFFAOYSA-N opicapone Chemical compound CC1=C(Cl)C(C)=[N+]([O-])C(Cl)=C1C1=NOC(C=2C=C(C(O)=C(O)C=2)[N+]([O-])=O)=N1 ASOADIZOVZTJSR-UHFFFAOYSA-N 0.000 claims 2
- 210000001428 peripheral nervous system Anatomy 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 230000004962 physiological condition Effects 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000005000 thioaryl group Chemical group 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 125000000815 N-oxide group Chemical group 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- -1 phosphate ester Chemical class 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical group [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 claims 1
- JOYRKODLDBILNP-UHFFFAOYSA-N urethane group Chemical group NC(=O)OCC JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161441988P | 2011-02-11 | 2011-02-11 | |
| US61/441,988 | 2011-02-11 | ||
| PCT/GB2011/052056 WO2012107708A1 (en) | 2011-02-11 | 2011-10-21 | Administration regime for nitrocatechols |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016220958A Division JP6389498B2 (ja) | 2011-02-11 | 2016-11-11 | ニトロカテコールの投与計画 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014505096A JP2014505096A (ja) | 2014-02-27 |
| JP2014505096A5 true JP2014505096A5 (enExample) | 2014-12-18 |
| JP6148985B2 JP6148985B2 (ja) | 2017-06-14 |
Family
ID=44999798
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013553014A Active JP6148985B2 (ja) | 2011-02-11 | 2011-10-21 | ニトロカテコールの投与計画 |
| JP2016220958A Active JP6389498B2 (ja) | 2011-02-11 | 2016-11-11 | ニトロカテコールの投与計画 |
| JP2018153722A Active JP6568274B2 (ja) | 2011-02-11 | 2018-08-17 | ニトロカテコールの投与計画 |
| JP2019142271A Active JP6843930B2 (ja) | 2011-02-11 | 2019-08-01 | ニトロカテコールの投与計画 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016220958A Active JP6389498B2 (ja) | 2011-02-11 | 2016-11-11 | ニトロカテコールの投与計画 |
| JP2018153722A Active JP6568274B2 (ja) | 2011-02-11 | 2018-08-17 | ニトロカテコールの投与計画 |
| JP2019142271A Active JP6843930B2 (ja) | 2011-02-11 | 2019-08-01 | ニトロカテコールの投与計画 |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US20140045900A1 (enExample) |
| EP (2) | EP3831382A1 (enExample) |
| JP (4) | JP6148985B2 (enExample) |
| AU (1) | AU2011358842B2 (enExample) |
| BR (2) | BR112013007380A2 (enExample) |
| CA (1) | CA2826080C (enExample) |
| CY (1) | CY1124022T1 (enExample) |
| DK (1) | DK2672973T3 (enExample) |
| ES (1) | ES2855162T3 (enExample) |
| HR (1) | HRP20210474T1 (enExample) |
| HU (1) | HUE054072T2 (enExample) |
| LT (1) | LT2672973T (enExample) |
| PL (1) | PL2672973T3 (enExample) |
| PT (1) | PT2672973T (enExample) |
| RS (1) | RS61643B1 (enExample) |
| RU (1) | RU2639131C2 (enExample) |
| SI (1) | SI2672973T1 (enExample) |
| WO (1) | WO2012107708A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8168793B2 (en) | 2005-07-26 | 2012-05-01 | Portela & Ca., S.A. | Nitrocatechol derivatives as COMT inhibitors |
| EP1845097A1 (en) | 2006-04-10 | 2007-10-17 | Portela & Ca., S.A. | Oxadiazole derivatives as COMT inhibitors |
| PL2481410T3 (pl) | 2007-01-31 | 2017-03-31 | Bial - Portela & Ca., S.A. | Pochodne nitrokatecholu jako inhibitory COMT podawane w określonym schemacie dawkowania |
| CL2009000628A1 (es) | 2008-03-17 | 2010-04-09 | Bial Portela & Companhia S A | Forma cristalina de 5-[3-(2,5-dicloro-4,6-dimetil-1-oxi-piridin-3-il)-[1,2,4]oxadiazol-5-il]-3-nitrobenceno-1,2-diol, composicion farmaceutica que la comprende, proceso para obtenerla y su uso para tratar trastornos del animo, enfermedad de parkinson y trastornos parkinsonianos, alteraciones gastrointestinales, entre otros. |
| US9132094B2 (en) | 2009-04-01 | 2015-09-15 | Bial—Portela & Ca, S.A. | Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof |
| US20140045900A1 (en) | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
| PT2791134T (pt) | 2011-12-13 | 2019-12-18 | BIAL PORTELA & Cª S A | Composto químico útil como intermediário para a preparação de um inibidor de catecol-o-metiltransferase |
| RU2017120184A (ru) * | 2014-11-28 | 2018-12-28 | БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. | Лекарства для замедления течения болезни паркинсона |
| TW201720443A (zh) | 2015-10-09 | 2017-06-16 | 梯瓦製藥國際有限責任公司 | 用以治療帕金森氏症之經氘化左旋多巴、碳度巴、以及奧匹卡朋的組合 |
| CN105677240B (zh) * | 2015-12-30 | 2019-04-23 | 上海联影医疗科技有限公司 | 数据删除方法及系统 |
| EP3860602A1 (en) | 2018-10-05 | 2021-08-11 | Neurocrine Biosciences, Inc. | Methods for the administration of comt inhibitors |
| US12097193B2 (en) | 2018-10-05 | 2024-09-24 | Bial—Portela & Ca, S.A. | Methods for the administration of COMT inhibitors |
| JP2020023540A (ja) * | 2019-10-11 | 2020-02-13 | ノヴィファーマ，エス．アー． | パーキンソン病を遅延させるための医薬 |
| JP7251026B2 (ja) | 2019-11-14 | 2023-04-04 | 国立大学法人九州大学 | ポリマー化合物およびコーティング組成物 |
| GB202016425D0 (en) * | 2020-10-16 | 2020-12-02 | Bial Portela & Ca Sa | Treatment regimens for parkinson's disease |
| KR20230118933A (ko) * | 2020-12-17 | 2023-08-14 | 바이알 - 포르텔라 앤드 씨에이 에스에이 | 초기 특발성 파킨슨병에 대한 치료 요법 |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1532178A (en) | 1921-07-25 | 1925-04-07 | Louis A Godbold | Lubricator |
| FR1260080A (fr) | 1960-03-22 | 1961-05-05 | Materiel De Forage Soc De Fab | Trépan à molettes étanche |
| US3647809A (en) | 1968-04-26 | 1972-03-07 | Chinoin Gyogyszer Es Vegyeszet | Certain pyridyl-1 2 4-oxadiazole derivatives |
| US4022901A (en) | 1975-03-05 | 1977-05-10 | E. R. Squibb & Sons, Inc. | 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles |
| US4264573A (en) | 1979-05-21 | 1981-04-28 | Rowell Laboratories, Inc. | Pharmaceutical formulation for slow release via controlled surface erosion |
| US4386668A (en) | 1980-09-19 | 1983-06-07 | Hughes Tool Company | Sealed lubricated and air cooled rock bit bearing |
| US5236952A (en) | 1986-03-11 | 1993-08-17 | Hoffmann-La Roche Inc. | Catechol derivatives |
| DK175069B1 (da) | 1986-03-11 | 2004-05-24 | Hoffmann La Roche | Pyrocatecholderivater |
| YU213587A (en) | 1986-11-28 | 1989-06-30 | Orion Yhtymae Oy | Process for obtaining new pharmacologic active cateholic derivatives |
| DE3840954A1 (de) | 1988-12-05 | 1990-06-07 | Shell Int Research | Herstellung von 2-chlornicotinsaeureestern |
| EP0462639A1 (en) | 1990-06-05 | 1991-12-27 | Shell Internationale Researchmaatschappij B.V. | Preparation of 2-chloropyridine derivatives |
| DK0487774T3 (da) | 1990-11-29 | 1994-11-21 | Wei Ming Pharmaceutical Mfg Co | Hjælpestof til direkte tablettering |
| WO1993013083A1 (en) | 1991-12-31 | 1993-07-08 | Fujisawa Pharmaceutical Co., Ltd. | Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity |
| US6361794B1 (en) | 1996-06-12 | 2002-03-26 | Basf Corporation | Method of making ibuprofen and narcotic analgesic composition |
| DE19628617A1 (de) | 1996-07-16 | 1998-01-22 | Basf Ag | Direkttablettierhilfsmittel |
| US6206110B1 (en) | 1996-09-09 | 2001-03-27 | Smith International, Inc. | Protected lubricant reservoir with pressure control for sealed bearing earth boring drill bit |
| US5788987A (en) * | 1997-01-29 | 1998-08-04 | Poli Industria Chimica Spa | Methods for treating early morning pathologies |
| WO1999048484A2 (en) | 1998-03-27 | 1999-09-30 | Pharmacia & Upjohn Company | Use of cabergoline in the treatment of restless legs syndrome |
| AU762245B2 (en) | 1998-09-18 | 2003-06-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
| GB2344819A (en) | 1998-12-18 | 2000-06-21 | Portela & Ca Sa | 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones |
| FI109453B (fi) * | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
| IL131037A (en) | 1999-07-22 | 2004-06-20 | Israel Atomic Energy Comm | Method for making threedimensional photonic band-gap crystals |
| PL353825A1 (en) | 1999-08-19 | 2003-12-01 | Nps Pharmaceuticals, Inc.Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| US6660753B2 (en) | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| FI20000635A0 (fi) | 2000-03-17 | 2000-03-17 | Orion Yhtymae Oyj | COMT-inhibiittoreiden käyttö analgeettina |
| SE0001438D0 (sv) | 2000-04-18 | 2000-04-18 | Axon Chemicals Bv | New chemical compounds and their use in therapy |
| DE10029201A1 (de) | 2000-06-19 | 2001-12-20 | Basf Ag | Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung |
| GB2363792A (en) | 2000-06-21 | 2002-01-09 | Portela & Ca Sa | Nitrocatechols |
| CN1166626C (zh) | 2000-08-30 | 2004-09-15 | 李凌松 | 三或四取代苯基化合物、其制备方法及应用 |
| WO2002044209A2 (en) | 2000-11-28 | 2002-06-06 | Zymogenetics, Inc. | Cytonkine receptor zcytor19 |
| CA2436739A1 (en) | 2000-12-26 | 2002-07-04 | Takeda Chemical Industries, Ltd. | Combination agent |
| US20040097555A1 (en) | 2000-12-26 | 2004-05-20 | Shinegori Ohkawa | Concomitant drugs |
| KR100777169B1 (ko) | 2001-01-29 | 2007-11-16 | 시오노기세이야쿠가부시키가이샤 | 5-메틸-1-페닐-2-(1ｈ)-피리돈을 활성 성분으로서함유하는 의약 제제 |
| EP1379525B1 (en) | 2001-02-21 | 2007-10-10 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| JP2004534779A (ja) | 2001-05-30 | 2004-11-18 | エルジー ライフサイエンス リミテッド | 疾病治療用プロテインキナーゼ阻害剤 |
| CN1638776A (zh) | 2001-06-08 | 2005-07-13 | 西托维亚公司 | 取代的3－芳基－5－芳基－[1,2,4]－噁二唑和类似物 |
| US6627646B2 (en) | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
| EP1408964B1 (en) | 2001-07-26 | 2007-01-24 | MERCK PATENT GmbH | Use of 2- 5-(4-fluorophenyl)-3-pyridylmethylaminomethyl|-chromane and its physiologically acceptable salts |
| JP4379853B2 (ja) | 2001-10-05 | 2009-12-09 | 惠民製藥股▲分▼有限公司 | 直接錠剤化用調合物および補助剤の調合方法 |
| JP2004115374A (ja) | 2002-09-24 | 2004-04-15 | Masayuki Tanno | 一酸化窒素供与剤としてのピリジン誘導体 |
| WO2004058253A1 (en) | 2002-12-18 | 2004-07-15 | Cytovia, Inc. | 3,5-disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| WO2004058163A2 (en) | 2002-12-23 | 2004-07-15 | Merck Frosst Canada & Co. | Pharmaceutical compositions and method of treating parkinson's disease |
| WO2005006945A2 (en) | 2003-07-03 | 2005-01-27 | The Salk Institute For Biological Studies | Methods for treating neural disorders and compounds useful therefor |
| US7226920B2 (en) | 2003-08-06 | 2007-06-05 | Vertex Pharmaceuticals Inc. | Aminotriazole compounds useful as inhibitors of protein kinases |
| DE10338174A1 (de) | 2003-08-20 | 2005-03-24 | Lts Lohmann Therapie-Systeme Ag | Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit |
| AU2004275470B2 (en) | 2003-09-29 | 2010-12-02 | Novo Nordisk Health Care Ag | Improved stability of progestogen formulations |
| US7300406B2 (en) | 2003-09-30 | 2007-11-27 | Carter Vandette B | Medical examination apparatus |
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| WO2005105780A2 (en) | 2004-04-28 | 2005-11-10 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of rock and other protein kinases |
| EP1625849A1 (en) | 2004-08-09 | 2006-02-15 | Liconsa, Liberacion Controlada de Sustancias Activas, S.A. | Pharmaceutical composition comprising drospirenone and ethynylestradiol |
| GB0510143D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
| US20060173074A1 (en) | 2004-11-10 | 2006-08-03 | Juha Ellmen | Treatment of restless legs syndrome |
| EP1827453A1 (en) | 2004-12-06 | 2007-09-05 | Themis Laboratories Private Limited | Sulfonylurea compositions and a process for its preparation |
| US20080051441A1 (en) | 2004-12-28 | 2008-02-28 | Astrazeneca Ab | Aryl Sulphonamide Modulators |
| JP2008525524A (ja) | 2004-12-28 | 2008-07-17 | アストラゼネカ・アクチエボラーグ | アリールスルホンアミドモジュレーター |
| WO2006114400A1 (en) | 2005-04-26 | 2006-11-02 | Neurosearch A/S | Novel oxadiazole derivatives and their medical use |
| US20060257473A1 (en) | 2005-05-11 | 2006-11-16 | Porranee Puranajoti | Extended release tablet |
| GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| ATE530519T1 (de) | 2005-06-03 | 2011-11-15 | Abbott Lab | Cyclobutylaminderivate |
| JP2007024970A (ja) | 2005-07-12 | 2007-02-01 | Miyakawa:Kk | 液晶表示装置の開口効率を上昇させるための樹脂レンズ製造法及びその製造装置 |
| US20090000437A1 (en) | 2005-07-14 | 2009-01-01 | Provo Craft And Novelty, Inc. | Methods for Cutting |
| US8168793B2 (en) * | 2005-07-26 | 2012-05-01 | Portela & Ca., S.A. | Nitrocatechol derivatives as COMT inhibitors |
| FR2889525A1 (fr) | 2005-08-04 | 2007-02-09 | Palumed Sa | Nouveaux derives de polyquinoleines et leur utilisation therapeutique. |
| US20070048384A1 (en) | 2005-08-26 | 2007-03-01 | Joerg Rosenberg | Pharmaceutical compositions |
| WO2007034024A2 (en) | 2005-09-21 | 2007-03-29 | Orion Corporation | Treatment of symptoms of parkinson' s disease |
| WO2007061862A2 (en) | 2005-11-18 | 2007-05-31 | Janssen Pharmaceutica N.V. | 2-keto-oxazoles as modulators of fatty acid amide hydrolase |
| WO2007063946A1 (ja) | 2005-11-30 | 2007-06-07 | Fujifilm Ri Pharma Co., Ltd. | アミロイドの凝集及び／又は沈着に起因する疾患の診断薬及び治療薬 |
| GB0606774D0 (en) | 2006-04-03 | 2006-05-10 | Novartis Ag | Organic compounds |
| EP1845097A1 (en) * | 2006-04-10 | 2007-10-17 | Portela & Ca., S.A. | Oxadiazole derivatives as COMT inhibitors |
| PE20080906A1 (es) | 2006-08-17 | 2008-07-05 | Kemia Inc | Derivados heteroarilo como inhibidores de citocina |
| US20080167286A1 (en) | 2006-12-12 | 2008-07-10 | Abbott Laboratories | Pharmaceutical compositions and their methods of use |
| US8486979B2 (en) | 2006-12-12 | 2013-07-16 | Abbvie Inc. | 1,2,4 oxadiazole compounds and methods of use thereof |
| JP2008162955A (ja) | 2006-12-28 | 2008-07-17 | Chugai Pharmaceut Co Ltd | バリン含有高密度顆粒剤 |
| PL2481410T3 (pl) * | 2007-01-31 | 2017-03-31 | Bial - Portela & Ca., S.A. | Pochodne nitrokatecholu jako inhibitory COMT podawane w określonym schemacie dawkowania |
| PE20081891A1 (es) | 2007-03-22 | 2008-12-27 | Opko Health Inc | Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas |
| KR101669432B1 (ko) | 2007-08-27 | 2016-10-26 | 다트 뉴로사이언스 (케이만) 엘티디. | 치료적 이속사졸 화합물 |
| EP2259777A2 (en) | 2008-02-28 | 2010-12-15 | BIAL - Portela & Ca., S.A. | Pharmaceutical composition for poorly soluble drugs |
| CL2009000628A1 (es) | 2008-03-17 | 2010-04-09 | Bial Portela & Companhia S A | Forma cristalina de 5-[3-(2,5-dicloro-4,6-dimetil-1-oxi-piridin-3-il)-[1,2,4]oxadiazol-5-il]-3-nitrobenceno-1,2-diol, composicion farmaceutica que la comprende, proceso para obtenerla y su uso para tratar trastornos del animo, enfermedad de parkinson y trastornos parkinsonianos, alteraciones gastrointestinales, entre otros. |
| TR201906117T4 (tr) * | 2008-07-29 | 2019-05-21 | Bial Portela & Ca Sa | Nitrokatesollere yönelik uygulama rejimi. |
| US20100256194A1 (en) | 2009-04-01 | 2010-10-07 | Bial - Portela & Ca, S.A. | Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same |
| US9132094B2 (en) | 2009-04-01 | 2015-09-15 | Bial—Portela & Ca, S.A. | Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof |
| US8294760B2 (en) * | 2009-04-21 | 2012-10-23 | Samsung Techwin Co., Ltd. | Electronic part recognition apparatus and chip mounter having the same |
| CN102781424B (zh) * | 2010-03-04 | 2016-03-30 | 奥赖恩公司 | 左旋多巴、卡比多巴和恩他卡朋用于治疗帕金森病的应用 |
| US20140045900A1 (en) * | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
| PT2791134T (pt) | 2011-12-13 | 2019-12-18 | BIAL PORTELA & Cª S A | Composto químico útil como intermediário para a preparação de um inibidor de catecol-o-metiltransferase |
| RU2017120184A (ru) | 2014-11-28 | 2018-12-28 | БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. | Лекарства для замедления течения болезни паркинсона |
-
2011
- 2011-10-12 US US13/583,375 patent/US20140045900A1/en not_active Abandoned
- 2011-10-21 RS RS20210351A patent/RS61643B1/sr unknown
- 2011-10-21 WO PCT/GB2011/052056 patent/WO2012107708A1/en not_active Ceased
- 2011-10-21 AU AU2011358842A patent/AU2011358842B2/en active Active
- 2011-10-21 LT LTEP11785058.6T patent/LT2672973T/lt unknown
- 2011-10-21 BR BR112013007380A patent/BR112013007380A2/pt not_active Application Discontinuation
- 2011-10-21 JP JP2013553014A patent/JP6148985B2/ja active Active
- 2011-10-21 EP EP20217676.4A patent/EP3831382A1/en active Pending
- 2011-10-21 RU RU2013139414A patent/RU2639131C2/ru active
- 2011-10-21 ES ES11785058T patent/ES2855162T3/es active Active
- 2011-10-21 PL PL11785058T patent/PL2672973T3/pl unknown
- 2011-10-21 CA CA2826080A patent/CA2826080C/en active Active
- 2011-10-21 DK DK11785058.6T patent/DK2672973T3/da active
- 2011-10-21 EP EP11785058.6A patent/EP2672973B1/en active Active
- 2011-10-21 HR HRP20210474TT patent/HRP20210474T1/hr unknown
- 2011-10-21 BR BR112013020424-9A patent/BR112013020424A2/pt not_active Application Discontinuation
- 2011-10-21 HU HUE11785058A patent/HUE054072T2/hu unknown
- 2011-10-21 SI SI201131963T patent/SI2672973T1/sl unknown
- 2011-10-21 PT PT117850586T patent/PT2672973T/pt unknown
-
2013
- 2013-08-09 US US13/963,621 patent/US10065944B2/en active Active
-
2016
- 2016-11-11 JP JP2016220958A patent/JP6389498B2/ja active Active
-
2018
- 2018-08-17 JP JP2018153722A patent/JP6568274B2/ja active Active
- 2018-08-28 US US16/114,430 patent/US12129247B2/en active Active
-
2019
- 2019-08-01 JP JP2019142271A patent/JP6843930B2/ja active Active
-
2021
- 2021-03-23 CY CY20211100250T patent/CY1124022T1/el unknown
-
2024
- 2024-10-23 US US18/924,015 patent/US20250276963A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014505096A5 (enExample) | ||
| RU2013139414A (ru) | Режим введения для нитрокатехолов | |
| RU2010154173A (ru) | Режим введения нитрокатехолов | |
| JP2015511638A5 (enExample) | ||
| JP2011173928A5 (enExample) | ||
| JP2009530398A5 (enExample) | ||
| JP2020512337A5 (enExample) | ||
| JP2013533253A5 (enExample) | ||
| EA200901146A1 (ru) | Твердые лекарственные формы, содержащие алискирен и его фармацевтически приемлемые соли | |
| WO2022225902A1 (en) | Treatment of cns diseases with sgc stimulators | |
| JP2014504648A5 (enExample) | ||
| RU2009145537A (ru) | Терапевтические соединения | |
| JP2013526579A5 (enExample) | ||
| RU2016110546A (ru) | Комбинированная лекарственная терапия | |
| EP2982382A1 (en) | Compounds for preventing ototoxicity | |
| EP4605080A1 (en) | Treatment of mitochondrial diseases with sgc stimulators | |
| JPWO2022211052A5 (enExample) | ||
| CN105530929B (zh) | 3‑羧基‑n‑乙基‑n,n‑二甲基丙‑1‑铵或其药学上可接受的盐在预防和治疗糖尿病中的用途 | |
| JP2016193903A5 (enExample) | ||
| TH132267A (th) | อนุพันธ์ไพราโซล |